• Publications
  • Influence
Is quality of life different between diabetic and non-diabetic people? The importance of cardiovascular risks
TLDR
The presence of established cardiovascular disease and/or cardiovascular risk factors, specially obesity, account for impaired quality of life in people with diabetes.
Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment
TLDR
ACL/FF 400/12 µg was a cost-saving therapy in patients with moderate-to-severe COPD in Spain, and provided equivalent effects compared to TIO/OLO 5/5 g.
Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain
TLDR
Age, eosinophilia, exacerbations and FEV1 were associated with greater resource utilization and costs for the health system, and total annual asthma costs and resource use were greater in patients with ≥300 cells/μl.
Costs and healthcare utilisation of patients with heart failure in Spain
TLDR
During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant, and drugs that reduce HF hospitalization may be helpful to reduce HF burden.
A Comparison of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Conventional Best Practice in Asthma Management in Spain
TLDR
A simplified regimen using budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) was at least as effective at improving clinical control compared with CBP with a significantly lower ICS dose and lower drug costs.
Costs and healthcare utilisation of patients with chronic kidney disease in Spain
TLDR
Between 2015 and 2019, costs of patients with CKD in Spain were high, with cardiovascular hospitalizations as the key determinant, and medication costs were responsible for only a small proportion of total CKD costs.
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain
TLDR
For the treatment of dyslipidemic patients with high CV risk, rosuVastatin is more effective than generic atorvastatin in terms of survival and quality-of-life adjusted survival, with incremental cost-effectiveness ratios within the range generally used in Spain, in most sub-populations defined by various combinations of CV risk factors.
...
...